Related Experiment Videos
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines
1School of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Abstract:
The tumour antigen ErbB-2 belongs to the epidermal growth factor receptor family. Numerous studies have shown that ErbB-2 is overexpressed in many cancers and it is prognostically important in a subset of malignancies. It is well recognised that this receptor has many characteristics that make it an excellent target for tumour-specific immunotherapy. One anti-ErbB-2 monoclonal antibody, Herceptin or TrastuzuMab, has already shown clinical efficacy for the treatment of metastatic breast cancer. However, despite this success, it is still currently unclear how monoclonal antibodies inhibit tumour growth in vivo. This review will summarise the biological activities of a range of anti-ErbB-2 Mabs, as well as their possible mechanisms of action. In addition, as an active mode of immunotherapy, the current vaccine strategies for inducing or enhancing ErbB-2-specific immunity will also be discussed. It is anticipated that a better understanding of the activities of anti-ErbB-2 Mabs will aid in the development of both passive and active immunotherapies against this important receptor.
Insights
This review explores ErbB-2 targeted immunotherapies, including monoclonal antibodies like Herceptin and vaccine strategies. Understanding their mechanisms can improve cancer treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- ErbB-2, an epidermal growth factor receptor family member, is overexpressed in various cancers.
- ErbB-2 overexpression is prognostically significant in certain malignancies.
- The receptor's characteristics make it a prime target for tumor-specific immunotherapy.
Purpose of the Study:
- To review the biological activities and mechanisms of action of anti-ErbB-2 monoclonal antibodies (mAbs).
- To discuss current vaccine strategies for ErbB-2-specific immunity.
- To enhance the development of passive and active immunotherapies targeting ErbB-2.
Main Methods:
- Review of existing literature on anti-ErbB-2 monoclonal antibodies.
- Analysis of biological activities and proposed mechanisms of action.
- Summary of current research on ErbB-2-targeted vaccine strategies.
Main Results:
- Herceptin (Trastuzumab), an anti-ErbB-2 mAb, demonstrates clinical efficacy in metastatic breast cancer.
- The precise in vivo mechanisms by which mAbs inhibit tumor growth are still under investigation.
- Various anti-ErbB-2 mAbs exhibit diverse biological activities.
Conclusions:
- Further understanding of anti-ErbB-2 mAb activities is crucial for advancing cancer immunotherapy.
- Both passive (mAbs) and active (vaccines) immunotherapies targeting ErbB-2 hold significant therapeutic potential.
- Continued research is needed to elucidate mechanisms and optimize treatment strategies.